These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

708 related articles for article (PubMed ID: 14508361)

  • 21. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts.
    Hoegh-Petersen M; Goodyear D; Geddes MN; Liu S; Ugarte-Torres A; Liu Y; Walker JT; Fonseca K; Daly A; Duggan P; Stewart D; Russell JA; Storek J
    Bone Marrow Transplant; 2011 Aug; 46(8):1104-12. PubMed ID: 21057556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience.
    Pinho-Apezzato ML; Tannuri U; Tannuri AC; Mello ES; Lima F; Gibelli NE; Santos MM; Ayoub AA; Maksoud-Filho JG; Velhote MC; Silva MM; Andrade WC; Miyatani HT
    Transplant Proc; 2010 Jun; 42(5):1763-8. PubMed ID: 20620519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
    Taylor AL; Marcus R; Bradley JA
    Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
    Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Posttransplant lymphoproliferative disorder in pediatric bone marrow transplant recipients: disseminated disease of donor origin demonstrated by fluorescence in situ hybridization.
    Lones MA; Lopez-Terrada D; Shintaku IP; Rosenthal J; Said JW
    Arch Pathol Lab Med; 1998 Aug; 122(8):708-14. PubMed ID: 9701332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
    Subklewe M; Marquis R; Choquet S; Leblond V; Garnier JL; Hetzer R; Swinnen LJ; Oertel S; Papp-Vary M; Gonzalez-Barca E; Hepkema BG; Schoenemann C; May J; Pezzutto A; Riess H
    Transplantation; 2006 Oct; 82(8):1093-100. PubMed ID: 17060859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic drug sensitivity of Epstein-Barr virus transformed lymphoblastoid B-cells.
    Markasz L; Stuber G; Flaberg E; Jernberg AG; Eksborg S; Olah E; Skribek H; Szekely L
    BMC Cancer; 2006 Nov; 6():265. PubMed ID: 17101045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.
    Khanna R; Bell S; Sherritt M; Galbraith A; Burrows SR; Rafter L; Clarke B; Slaughter R; Falk MC; Douglass J; Williams T; Elliott SL; Moss DJ
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10391-6. PubMed ID: 10468618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease.
    Burns DM; Crawford DH
    Blood Rev; 2004 Sep; 18(3):193-209. PubMed ID: 15183903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease.
    Verschuuren E; van der Bij W; de Boer W; Timens W; Middeldorp J; The TH
    J Med Virol; 2003 Feb; 69(2):258-66. PubMed ID: 12683416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Post-transplant lymphoproliferative disorder limited to the skin.
    Samolitis NJ; Bharadwaj JS; Weis JR; Harris RM
    J Cutan Pathol; 2004 Jul; 31(6):453-7. PubMed ID: 15186434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microsatellite analysis in post-transplantation lymphoproliferative disorder to determine donor/recipient origin.
    Ng IO; Shek TW; Thung SN; Ye MM; Lo CM; Fan ST; Lee JM; Chan KW; Cheung AN
    Mod Pathol; 2000 Nov; 13(11):1180-5. PubMed ID: 11106074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discrimination of Epstein-Barr virus-related posttransplant lymphoproliferations from acute rejection in lung allograft recipients.
    Rosendale B; Yousem SA
    Arch Pathol Lab Med; 1995 May; 119(5):418-23. PubMed ID: 7748068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
    Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
    Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The morphologic and molecular genetic categories of posttransplantation lymphoproliferative disorders are clinically relevant.
    Chadburn A; Chen JM; Hsu DT; Frizzera G; Cesarman E; Garrett TJ; Mears JG; Zangwill SD; Addonizio LJ; Michler RE; Knowles DM
    Cancer; 1998 May; 82(10):1978-87. PubMed ID: 9587133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
    Dharnidharka VR; Douglas VK; Hunger SP; Fennell RS
    Pediatr Transplant; 2004 Feb; 8(1):87-90. PubMed ID: 15009846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations.
    Walker RC; Paya CV; Marshall WF; Strickler JG; Wiesner RH; Velosa JA; Habermann TM; Daly RC; McGregor CG
    J Heart Lung Transplant; 1995; 14(2):214-21. PubMed ID: 7779838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.